Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.36 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18647927 | 0.98 | OPRM1 (0.38) | OPRM1OPRD1OPRK1OPRL1AOC3 | |
| SCHEMBL21555784 | 0.95 | OPRM1 (0.39) | OPRM1OPRD1OPRK1OPRL1AOC3 | |
| SCHEMBL19101512 | 0.95 | OPRM1 (0.39) | OPRM1OPRD1OPRK1OPRL1AOC3 | |
| SCHEMBL21732183 | 0.95 | OPRM1 (0.42) | OPRM1OPRD1OPRK1OPRL1AOC3 | |
| SCHEMBL21555772 | 0.93 | OPRM1 (0.41) | OPRM1OPRD1OPRK1OPRL1AOC3 | |
| SCHEMBL17320101 | 0.91 | AOC3 (0.42) | AOC3HDAC4HDAC7HDAC5IDO1 | |
| SCHEMBL30862486 | 0.88 | NR1I2 (0.39) | — | |
| SCHEMBL19003606 | 0.84 | AOC3 (0.41) | AOC3HDAC4HDAC7HDAC5IDO1 | |
| SCHEMBL28710729 | 0.82 | NR1I2 (0.44) | — | |
| SCHEMBL22795875 | 0.81 | OPRM1 (0.39) | OPRM1OPRD1OPRK1OPRL1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312576-A1 | 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER | UNIVERSITÉ DE TOURS (FR) | 2023-10-05 | — | — | US | disclosed |
| US-11033556-B2 | Bicyclic sulfonamides | ALIGOS THERAPEUTICS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200345749-A1 | BICYCLIC SULFONAMIDES | ALIGOS THERAPEUTICS, INC. | 2020-11-05 | — | — | US | disclosed |
| EP-2938344-B1 | PIPERAZINE-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME (US) | 2017-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11033556-B2 | Bicyclic sulfonamides | STS, SULT2A1, ARSA | OPRM1 3669/4885OPRD1 2666/4885OPRK1 3161/4885 |
| US-20200345749-A1 | BICYCLIC SULFONAMIDES | STS, SULT2A1, ARSA | OPRM1 3669/4885OPRD1 2666/4885OPRK1 3161/4885 |
| US-20230312576-A1 | 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER | LIMK1, LIMK2, ROCK1 | OPRM1 1510/4885OPRD1 420/4885OPRK1 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.